v3.25.2
Net Loss Per Share
6 Months Ended
Jun. 30, 2025
Net Loss Per Share  
Net Loss Per Share

14. Net Loss Per Share

The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of Common Stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of Common Stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.

The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended June 30, 2025 and 2024:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to ASP Isotopes Inc. shareholders before deemed dividend on warrant to purchase common stock

 

$

(75,062,857

)

 

$

(8,932,925

)

 

$

(83,509,054

)

 

$

(15,881,010

)

Deemed dividend on warrant to purchase common stock

 

 

 

 

 

(2,779,659

)

 

 

 

 

 

(2,779,659

)

Net loss attributable to ASP Isotopes Inc. shareholders

 

 

(75,062,857

)

 

 

(11,712,584

)

 

 

(83,509,054

)

 

 

(18,660,669

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common stock outstanding, basic and diluted

 

 

73,009,938

 

 

 

49,136,009

 

 

 

71,256,809

 

 

 

46,848,926

 

Net loss per share, basic and diluted

 

 

(1.03

)

 

 

(0.24

)

 

 

(1.17

)

 

 

(0.40

)

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:

 

 

As of June 30,

 

 

2025

 

 

2024

 

Options to purchase common stock

 

 

2,431,000

 

 

 

2,731,000

 

Restricted stock

 

 

4,754,156

 

 

 

2,550,000

 

Warrants to purchase common stock

 

 

221,519

 

 

 

1,446,519

 

Total shares of common stock equivalents

 

 

7,406,675

 

 

 

6,727,519